

Federico Pea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5729880/publications.pdf>

Version: 2024-02-01

239
papers

8,215
citations

71102

41
h-index

62596

80
g-index

240
all docs

240
docs citations

240
times ranked

8174
citing authors

#	ARTICLE	IF	CITATIONS
1	An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 331-352.	4.4	7
2	Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?" <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0190821.	3.2	1
3	Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency. <i>Clinical Pharmacokinetics</i> , 2022, 61, 505-513.	3.5	2
4	A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , 2022, 11, 635-638.	4.0	1
5	Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like <i>Klebsiella pneumoniae</i> Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring. <i>Infectious Disease Reports</i> , 2022, 14, 88-92.	3.1	3
6	Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime-Avibactam-Based Regimens: A Report of Two Cases. <i>Microorganisms</i> , 2022, 10, 154.	3.6	13
7	Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignancies. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 641-650.	2.0	4
8	An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> in Critically Ill Adult Patients. <i>Antibiotics</i> , 2022, 11, 33.	3.7	15
9	Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106611.	2.5	36
10	Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients. <i>Critical Care</i> , 2022, 26, .	5.8	41
11	Management of patients with acute myeloid leukemia undergoing therapy with midostaurin: a focus on antifungal prophylaxis. <i>Hematological Oncology</i> , 2021, 39, 20-26.	1.7	0
12	Should the Clinical Pharmacologist Play a Role in the Multidisciplinary Team Managing Severe Necrotizing Soft-Tissue Infections?. <i>Clinical Pharmacokinetics</i> , 2021, 60, 403-407.	3.5	3
13	The role of procalcitonin in reducing antibiotics across the surgical pathway. <i>World Journal of Emergency Surgery</i> , 2021, 16, 15.	5.0	4
14	The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1125-1134.	4.4	11
15	Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies. <i>CNS Drugs</i> , 2021, 35, 345-384.	5.9	8
16	Population Pharmacokinetics and Monte Carlo Simulation for Dosage Optimization of Fosfomycin in the Treatment of Osteoarticular Infections in Patients without Renal Dysfunction. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	7
17	Population Pharmacokinetics of Dalbavancin and Dosing Consideration for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	28
18	Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 583-599.	3.1	31

#	ARTICLE	IF	CITATIONS
19	Authors' Reply to Cattaneo et al.: "Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6". <i>Clinical Pharmacokinetics</i> , 2021, 60, 833-834.	3.5	0
20	Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. <i>Clinical Microbiology and Infection</i> , 2021, 27, 671-686.	6.0	54
21	Diagnostic stewardship based on patient profiles: differential approaches in acute versus chronic infectious syndromes. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1373-1383.	4.4	5
22	An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAls Caused by Enterobacterales in Critically Ill Adult Patients. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 2461-2498.	2.7	14
23	Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1271-1289.	3.5	27
24	Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 737-747.	3.1	28
25	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , 2021, 10, 1837-1885.	4.0	28
26	Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis. <i>Mycoses</i> , 2021, 64, 1317-1327.	4.0	3
27	Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3349-3378.	4.3	34
28	Challenges in the management of chronic wound infections. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 26, 140-147.	2.2	56
29	A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings. <i>Frontiers in Pharmacology</i> , 2021, 12, 755075.	3.5	6
30	Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and <i>Pseudomonas aeruginosa</i> . <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106408.	2.5	12
31	A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant <i>Acinetobacter baumannii</i> bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 27, 294-298.	2.2	44
32	Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant <i>Klebsiella pneumoniae</i> carbapenemase-producing <i>Klebsiella pneumoniae</i> in a critically ill patient. <i>International Journal of Infectious Diseases</i> , 2021, 113, 213-217.	3.3	15
33	Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106445.	2.5	19
34	Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections. <i>Antibiotics</i> , 2021, 10, 1311.	3.7	47
35	Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant <i>Pseudomonas aeruginosa</i> (DTR-P) infections. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab188.	2.1	38
36	Impact of Maximizing C _{ss} /MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization. <i>Frontiers in Pharmacology</i> , 2021, 12, 781892.	3.5	12

#	ARTICLE	IF	CITATIONS
37	Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against <i>Aspergillus fumigatus</i> and <i>Aspergillus flavus</i> in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?. <i>Pharmaceutics</i> , 2021, 13, 2099.	4.5	12
38	Sonidegib for the Treatment of Advanced Basal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 582866.	2.8	18
39	Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e739-e740.	3.9	3
40	Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3029-3037.	3.0	24
41	Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and <i>P. aeruginosa</i> . <i>Pharmaceutics</i> , 2020, 12, 785.	4.5	6
42	Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1251-1260.	3.5	25
43	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. <i>Intensive Care Medicine</i> , 2020, 46, 1127-1153.	8.2	504
44	From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis. <i>Mycoses</i> , 2020, 63, 854-858.	4.0	4
45	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e474-e484.	3.9	772
46	Real-Time Therapeutic Drug Monitoring-Based Pharmacokinetic/Pharmacodynamic Optimization of Complex Antimicrobial Therapy in a Critically Ill Morbidly Obese Patient. <i>Grand Round/A Case Study. Therapeutic Drug Monitoring</i> , 2020, 42, 349-352.	2.0	7
47	A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: Application to critically ill pediatric patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 186, 113273.	2.8	67
48	The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 415-422.	4.4	25
49	Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 900-907.	1.7	19
50	Antifungal susceptibility testing in <i>Candida</i> , <i>Aspergillus</i> and <i>Cryptococcus</i> infections: are the MICs useful for clinicians?. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1024-1033.	6.0	23
51	Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?. <i>Infectious Diseases and Therapy</i> , 2020, 9, 137-149.	4.0	25
52	Acute wound infections management: the –Donâ€™tsâ€™ from a multidisciplinary expert panel. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 231-240.	4.4	13
53	Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4697-4711.	2.7	21
54	Assessment of the impact of clinical recommendations on antibiotic use for CAP and HCAP: results from an implementation program in an Academic Hospital. <i>Annali Di Igiene: Medicina Preventiva E Di Comunita</i> , 2020, 32, 344-356.	0.7	1

#	ARTICLE	IF	CITATIONS
55	Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3588-3595.	3.0	35
56	Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 819-827.	4.4	22
57	Ceftobiprole: drug evaluation and place in therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 689-698.	4.4	42
58	Treatment of <i>Candida</i> infections with fluconazole in adult liver transplant recipients: Is TDM-guided dosing adaptation helpful?. <i>Transplant Infectious Disease</i> , 2019, 21, e13113.	1.7	12
59	Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	63
60	Principles of Pharmacodynamics and Pharmacokinetics of Drugs Used in Extracorporeal Therapies. , 2019, , 892-896.e1.		1
61	Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1648-1655.	3.0	11
62	A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 1042-1042.	1.2	3
63	Interlaboratory Analysis of Isavuconazole Plasma Concentration Assays Among European Laboratories. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 657-664.	2.0	10
64	Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 266-269.	2.4	8
65	Ceftolozane/tazobactam: place in therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 307-320.	4.4	100
66	The current role of glycopeptides in the treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts. <i>Journal of Chemotherapy</i> , 2018, 30, 157-171.	1.5	0
67	Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1091-1092.	1.9	5
68	Actoxumab + bezlotoxumab combination: what promise for <i>Clostridium difficile</i> treatment?. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 469-476.	3.1	5
69	Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1399-1405.	3.5	13
70	Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications. <i>Clinical Pharmacokinetics</i> , 2018, 57, 177-189.	3.5	27
71	Ceftolozane/tazobactam for the treatment of MDR <i>Pseudomonas aeruginosa</i> left ventricular assist device infection as a bridge to heart transplant. <i>Infection</i> , 2018, 46, 263-265.	4.7	19
72	Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. <i>Clinical Pharmacokinetics</i> , 2018, 57, 989-1000.	3.5	26

#	ARTICLE	IF	CITATIONS
73	Physiological Manifestations of Critical Illness. , 2018, , 31-46.		1
74	Overview of antifungal dosing in invasive candidiasis. Journal of Antimicrobial Chemotherapy, 2018, 73, i33-i43.	3.0	31
75	Pharmacokinetics and drug metabolism of antibiotics in the elderly. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1087-1100.	3.3	26
76	Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient. European Journal of Clinical Pharmacology, 2018, 74, 1671-1672.	1.9	7
77	Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report. Drugs and Therapy Perspectives, 2018, 34, 402-403.	0.6	2
78	Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.. European Journal of Clinical Pharmacology, 2018, 74, 1449-1459.	1.9	6
79	Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-release tablets in adult patients with haematological malignancies. British Journal of Clinical Pharmacology, 2018, 84, 2544-2550.	2.4	20
80	Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?. Journal of Global Antimicrobial Resistance, 2018, 14, 238-241.	2.2	4
81	Procalcitonin-guided antibiotic therapy: an expert consensus. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1223-1229.	2.3	51
82	A 10-Year Experience of Therapeutic Drug Monitoring (<sc>TDM</sc>) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting <sc>TDM</sc> in the Majority of Patients?. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 303-308.	2.5	64
83	Limited sampling strategies for determining the area under the plasma concentration-time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis. International Journal of Antimicrobial Agents, 2017, 50, 23-28.	2.5	12
84	Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	24
85	Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?. International Journal of Antimicrobial Agents, 2017, 49, 255-258.	2.5	65
86	Î²-Blockers and Diltiazem Combinationâ€”Bear in Mind the Risk of Heart Block. JAMA Internal Medicine, 2017, 177, 1543.	5.1	2
87	Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1193-1200.	3.3	19
88	Pharmacodynamics of teicoplanin against MRSA. Journal of Antimicrobial Chemotherapy, 2017, 72, 3382-3389.	3.0	40
89	Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review. Journal of NeuroVirology, 2017, 23, 908-912.	2.1	6
90	Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	44

#	ARTICLE	IF	CITATIONS
91	Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2342-2350.	3.0	26
92	Monitoring Polypharmacy in Healthcare Systems through a Multi-Setting Survey: Should We Put More Attention on Long Term Care Facilities?. <i>Journal of Public Health Research</i> , 2016, 5, jphr.2016.745.	1.2	11
93	Urological Infections Due to Multidrug-Resistant Bacteria: What We Need to Know?. <i>Urologia</i> , 2016, 83, 21-26.	0.7	3
94	Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 153-159.	3.1	23
95	A 1Âyear retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 341-348.	2.4	18
96	Polytherapy and the risk of potentially inappropriate prescriptions (PIPs) among elderly and very elderly patients in three different settings (hospital, community, long-term care facilities) of the Friuli Venezia Giulia region, Italy: are the very elderl. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1070-1078.	1.9	24
97	Methicillin-resistant <i>Staphylococcus aureus</i> infections: A review of the currently available treatment options. <i>Journal of Global Antimicrobial Resistance</i> , 2016, 7, 178-186.	2.2	87
98	Reply. <i>Annals of Pharmacotherapy</i> , 2016, 50, 153-153.	1.9	0
99	Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1507-1520.	3.5	42
100	Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(<sc>CYP</sc>) Inhibitors and/or with <sc>CYP</sc> Inhibitors plus <sc>CYP</sc> Inducers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 118, 474-479.	2.5	34
101	Does Critical Illness Change Levofloxacin Pharmacokinetics?. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1459-1463.	3.2	17
102	Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1323-1329.	3.0	13
103	Immunologic and Pharmacologic Aspects in an Elderly Recipient of Liver Transplant With Pulmonary Aspergillosis and Multiple Comorbidities. <i>Experimental and Clinical Transplantation</i> , 2016, 14, 567-570.	0.5	2
104	Antiretroviral blood levels in <sc>HIV</sc>/<sc>HCV</sc>â€œcoinfected patients with cirrhosis after liver transplant: a report of three cases. <i>Transplant Infectious Disease</i> , 2015, 17, 147-153.	1.7	4
105	Everolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumonia. <i>Transplant Infectious Disease</i> , 2015, 17, 926-928.	1.7	6
106	A regional approach to Antimicrobial Stewardship: the Friuli Venezia Giulia program. <i>European Journal of Public Health</i> , 2015, 25, .	0.3	0
107	Risk factors associated with the onset of daptomycin non-susceptibility in <i>Staphylococcus aureus</i> infections in critically ill patients. <i>Intensive Care Medicine</i> , 2015, 41, 366-368.	8.2	13
108	Clinical pharmacological approach for balancing the use of daptomycin and linezolid in comparison with that of vancomycin in the treatment of MRSA-related infections. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 927-937.	4.4	0

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetics and Pharmacodynamics of Continuous-Infusion Meropenem in Pediatric Hematopoietic Stem Cell Transplant Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5535-5541.	3.2	16
110	Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis. <i>Annals of Pharmacotherapy</i> , 2015, 49, 978-985.	1.9	9
111	Antimicrobial treatment of bacterial infections in frail elderly patients: the difficult balance between efficacy, safety and tolerability. <i>Current Opinion in Pharmacology</i> , 2015, 24, 18-22.	3.5	14
112	Comparison of clinical characteristics of tuberculosis between two age groups at an Italian Tertiary Hospital. <i>Infection</i> , 2015, 43, 361-366.	4.7	2
113	Pharmacokinetics and Pharmacodynamics of Continuous Infusion Meropenem in Overweight, Obese, and Morbidly Obese Patients with Stable and Unstable Kidney Function: A Step Toward Dose Optimization for the Treatment of Severe Gram-Negative Bacterial Infections. <i>Clinical Pharmacokinetics</i> , 2015, 54, 933-941.	3.5	31
114	Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience. <i>Intensive Care Medicine</i> , 2015, 41, 2026-2028.	8.2	6
115	Linezolid underexposure in a patient co-treated with venlafaxine. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1285-1286.	1.9	10
116	Editorial overview: Anti-infectives: Current challenges and unmet needs in antimicrobial therapy. <i>Current Opinion in Pharmacology</i> , 2015, 24, iv-vi.	3.5	2
117	A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant Staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 81, 53-56.	1.8	5
118	Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 198-206.	3.0	33
119	Treatment options for community-acquired pneumonia in the elderly people. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 473-85.	4.4	8
120	Drugs and Blood Cells. , 2015, , 111-147.		0
121	Polypharmacy in an Italian Regional Health system: a survey on drugs use in different healthcare settings. <i>European Journal of Public Health</i> , 2014, 24, .	0.3	0
122	Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 570-571.	2.5	7
123	The effect of pathophysiology on pharmacokinetics in the critically ill patient – Concepts appraised by the example of antimicrobial agents. <i>Advanced Drug Delivery Reviews</i> , 2014, 77, 3-11.	13.7	351
124	Stability of Generic Meropenem Solutions for Administration by Continuous Infusion at Normal and Elevated Temperatures. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 674-676.	2.0	26
125	Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. <i>Infection</i> , 2014, 42, 207-210.	4.7	18
126	Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2585-2586.	3.0	23

#	ARTICLE	IF	CITATIONS
127	An international, multicentre survey of β -lactam antibiotic therapeutic drug monitoring practice in intensive care units. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1416-1423.	3.0	185
128	Educational and Organizational Interventions to Improve the Usefulness of Clinical Pharmacological Advice for Personalized Drug Dosing Based on Therapeutic Drug Monitoring. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 115, 432-437.	2.5	5
129	Daptomycin in solid organ transplantation: consideration of dosage adjustments in renal impairment. <i>Transplant Infectious Disease</i> , 2014, 16, 868-869.	1.7	1
130	Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMI ≥ 40 kg/m ²) Should Be Guided by Creatinine Clearance Estimates Based on Ideal Body Weight and Optimized by Therapeutic Drug Monitoring. <i>Clinical Pharmacokinetics</i> , 2014, 53, 753-762.	3.5	33
131	Population Pharmacokinetics of Teicoplanin in Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6920-6927.	3.2	29
132	Biliary pharmacodynamic exposure to linezolid in two liver transplant patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 567-568.	3.0	3
133	Identification and management of invasive mycoses in internal medicine: a road-map for physicians. <i>Internal and Emergency Medicine</i> , 2014, 9, 501-511.	2.0	23
134	Linezolid Underexposure in a Hypothyroid Patient on Levothyroxine Replacement Therapy. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 687-689.	2.0	13
135	Gentamicin once-daily in enterococcal endocarditis. <i>International Journal of Cardiology</i> , 2013, 168, 5033-5034.	1.7	12
136	Current pharmacological concepts for wise use of echinocandins in the treatment of Candida infections in septic critically ill patients. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 989-997.	4.4	9
137	The Clinical Relevance of Plasma Protein Binding Changes. <i>Clinical Pharmacokinetics</i> , 2013, 52, 1-8.	3.5	225
138	Occurrence and Extent of Bruising According to Duration of Administration of Subcutaneous Low-Molecular-Weight Heparin. <i>Journal of Cardiovascular Nursing</i> , 2013, 28, 473-482.	1.1	22
139	Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: Dose Intensification Coupled with Avoidance of Proton Pump Inhibitors Is Beneficial in Shortening Time to Effective Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6081-6084.	3.2	23
140	Plasma Pharmacokinetics of Antimicrobial Agents in Critically Ill Patients. <i>Current Clinical Pharmacology</i> , 2013, 8, 5-12.	0.6	23
141	Plasma Pharmacokinetics of Antimicrobial Agents in Critically Ill Patients. <i>Current Clinical Pharmacology</i> , 2013, 8, 5-12.	0.6	2
142	Plasma pharmacokinetics of antimicrobial agents in critically ill patients. <i>Current Clinical Pharmacology</i> , 2013, 8, 5-12.	0.6	39
143	Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2034-2042.	3.0	208
144	Antibiotic therapy in hematological neutropenic patients: what is the news?. <i>Leukemia Supplements</i> , 2012, 1, S20-S21.	0.1	0

#	ARTICLE	IF	CITATIONS
145	Dosing Nomograms for Attaining Optimum Concentrations of Meropenem by Continuous Infusion in Critically Ill Patients with Severe Gram-Negative Infections: a Pharmacokinetics/Pharmacodynamics-Based Approach. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6343-6348.	3.2	76
146	Pneumonia in frail older patients: an up to date. <i>Internal and Emergency Medicine</i> , 2012, 7, 415-424.	2.0	30
147	Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 17-24.	3.0	177
148	Successful Long-Term Treatment of Cerebral Nocardiosis with Unexpectedly Low Doses of Linezolid in an Immunocompromised Patient Receiving Complex Polytherapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3438-3440.	3.2	24
149	Italian Guidelines for Diagnosis, Prevention, and Treatment of Invasive Fungal Infections in Solid Organ Transplant Recipients. <i>Transplantation Proceedings</i> , 2011, 43, 2463-2471.	0.6	24
150	Effect of the Number of Samples on Bayesian and Non-linear Least-squares Individualization: A Study of Cyclosporin Treatment of Haematological Patients with Multidrug Resistance. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 50, 343-349.	2.4	8
151	Long-Term Outcomes of Orthotopic Liver Transplantation in Human Immunodeficiency Virus-Infected Patients and Comparison With Human Immunodeficiency Virus-Negative Cases. <i>Transplantation Proceedings</i> , 2011, 43, 1119-1122.	0.6	18
152	WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. <i>World Journal of Emergency Surgery</i> , 2011, 6, 2.	5.0	57
153	HIV-Infected Patients and Liver Transplantation: Who, When and Why. <i>Current HIV Research</i> , 2011, 9, 120-127.	0.5	7
154	Continuous Infusion May Improve the Efficacy of Vancomycin in Treatment of Experimental Endocarditis Due to Heterogeneous Vancomycin-Intermediate <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4496-4497.	3.2	2
155	TDM-Guided Therapy with Daptomycin and Meropenem in a Morbidly Obese, Critically Ill Patient. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1022-1022.	1.9	52
156	Vancomycin Way of Administration: Where is the Evidence?. <i>Clinical Infectious Diseases</i> , 2011, 53, 308-310.	5.8	6
157	Is the Use of Vancomycin Doses of At Least 1 g Every 8 Hours the Only Way to Achieve Optimal Trough Levels in Critically Ill Trauma Patients With Pneumonia and Normal Renal Function?. <i>Journal of Trauma</i> , 2010, 68, 748-749.	2.3	0
158	Therapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4605-4610.	3.2	172
159	Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. <i>International Journal of Infectious Diseases</i> , 2010, 14, S79-S92.	3.3	102
160	A multi-society position paper on the prevention and management of nosocomial and severe infections: the Italian Society for Infectious Diseases, the Italian Multidisciplinary Society of Hospital Infections, the Italian Society of Chemotherapy, the Italian Society of Respiratory Medicine, the Italian Society of Clinical Microbiology, the Italian Society of Microbiology, and GISIG (Italian Study Group) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	3.3	1
161	What Should Be the First-Choice Strategy To Maximize Posaconazole Exposure in Daily Clinical Practice?. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3608-3610.	3.2	7
162	Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1863-1867.	3.2	113

#	ARTICLE	IF	CITATIONS
163	Is the Minimum Inhibitory Concentration of Vancomycin an Infallible Predictor of the Clinical Outcome of <i>Staphylococcus aureus</i> Bacteremia Treated with Vancomycin?. <i>Clinical Infectious Diseases</i> , 2009, 49, 642-643.	5.8	6
164	The <i>Charta</i> of Milan: Basic Criteria for the Appropriate and Accurate Use of Antibiotics: Recommendations of the Italian Society of Chemotherapy. <i>Journal of Chemotherapy</i> , 2009, 21, 475-481.	1.5	2
165	Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock – does the dose matter?. <i>Critical Care</i> , 2009, 13, 214.	5.8	157
166	Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin. <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 379-382.	2.5	36
167	Penetration of Antibacterials into Bone. <i>Clinical Pharmacokinetics</i> , 2009, 48, 125-127.	3.5	17
168	Hallucinations During Voriconazole Therapy: Who Is at Higher Risk and Could Benefit From Therapeutic Drug Monitoring?. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 135-136.	2.0	4
169	Could De-escalation of Antibiotic Therapy be Feasible Even for Documented Methicillin-Resistant <i>Staphylococcus aureus</i> Ventilator-Associated Pneumonia?. <i>Journal of Trauma</i> , 2009, 67, 893-894.	2.3	5
170	Principles of Pharmacodynamics and Pharmacokinetics of Drugs Used in Extracorporeal Therapies. , 2009, , 1190-1194.		0
171	Is antimicrobial underexposure due to glomerular hyperfiltration a possible cause of increased mortality rate from bacterial infections in critically ill patients?. <i>Anaesthesia and Intensive Care</i> , 2009, 37, 323-4.	0.7	5
172	Penetration of antibacterials into bone: what do we really need to know for optimal prophylaxis and treatment of bone and joint infections?. <i>Clinical Pharmacokinetics</i> , 2009, 48, 125-7.	3.5	5
173	Should the Currently Recommended Twice-Daily Dosing Still Be Considered the Most Appropriate Regimen for Treating MRSA Ventilator-Associated Pneumonia with Vancomycin?. <i>Clinical Pharmacokinetics</i> , 2008, 47, 147-152.	3.5	28
174	Clinical Relevance of Pharmacokinetics and Pharmacodynamics in Cardiac Critical Care Patients. <i>Clinical Pharmacokinetics</i> , 2008, 47, 449-462.	3.5	30
175	Pharmacokinetic Interaction Between Everolimus and Antifungal Triazoles in a Liver Transplant Patient. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1711-1716.	1.9	27
176	Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 167-169.	3.0	9
177	Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. <i>Antiviral Therapy</i> , 2008, 13, 739-42.	1.0	1
178	Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. <i>Antiviral Therapy</i> , 2008, 13, 739-742.	1.0	7
179	What does it mean: Appropriate therapy for methicillin-resistant <i>Staphylococcus aureus</i> ?. <i>Critical Care Medicine</i> , 2007, 35, 991.	0.9	1
180	Major role of levofloxacin in the treatment of a case of <i>Listeria monocytogenes</i> meningitis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 137-139.	1.8	22

#	ARTICLE	IF	CITATIONS
181	Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections. Expert Review of Anti-Infective Therapy, 2007, 5, 255-270.	4.4	17
182	Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500mg oral dose. Pharmacological Research, 2007, 55, 38-41.	7.1	20
183	Pharmacokinetic Considerations for Antimicrobial Therapy in Patients Receiving Renal Replacement Therapy. Clinical Pharmacokinetics, 2007, 46, 997-1038.	3.5	174
184	Pharmacokinetic and Pharmacodynamic Aspects of Oral Moxifloxacin 400 mg/day in Elderly Patients with Acute Exacerbation of Chronic Bronchitis. Clinical Pharmacokinetics, 2006, 45, 287-295.	3.5	12
185	Pharmacokinetic and pharmacodynamic aspects of antimicrobial prophylaxis with teicoplanin in patients undergoing major vascular surgery. International Journal of Antimicrobial Agents, 2006, 27, 15-19.	2.5	3
186	The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin. International Journal of Antimicrobial Agents, 2006, 27, 344-350.	2.5	17
187	Treatment of Post-Traumatic Hand Staphylococcus aureus Osteomyelitis with Oral Linezolid. Journal of Chemotherapy, 2006, 18, 425-429.	1.5	2
188	Hyperlactacidemia Potentially Due to Linezolid Overexposure in a Liver Transplant Recipient. Clinical Infectious Diseases, 2006, 42, 434-435.	5.8	73
189	The Antimicrobial Therapy Puzzle: Could Pharmacokinetic-Pharmacodynamic Relationships Be Helpful in Addressing the Issue of Appropriate Pneumonia Treatment in Critically Ill Patients?. Clinical Infectious Diseases, 2006, 42, 1764-1771.	5.8	133
190	Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. Journal of Antimicrobial Chemotherapy, 2006, 58, 380-386.	3.0	44
191	Ceftazidime in Acute Myeloid Leukemia Patients with Febrile Neutropenia: Helpfulness of Continuous Intravenous Infusion in Maximizing Pharmacodynamic Exposure. Antimicrobial Agents and Chemotherapy, 2005, 49, 3550-3553.	3.2	49
192	Levofloxacin Disposition over Time in Aqueous Humor of Patients Undergoing Cataract Surgery. Antimicrobial Agents and Chemotherapy, 2005, 49, 2554-2557.	3.2	10
193	Antimicrobial Therapy in Critically Ill Patients. Clinical Pharmacokinetics, 2005, 44, 1009-1034.	3.5	316
194	Pharmacology of Drugs for Hyperuricemia. , 2004, 147, 35-46.		54
195	Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: A report of 2 cases. American Journal of Kidney Diseases, 2004, 44, 1097-1102.	1.9	34
196	Teicoplanin in Patients with Acute Leukaemia and Febrile Neutropenia. Clinical Pharmacokinetics, 2004, 43, 405-415.	3.5	74
197	Levofloxacin PK/PD: from Sequential Therapy Model to High Dosage for Critical Patients. Journal of Chemotherapy, 2004, 16, 8-10.	1.5	6
198	Pharmacokinetics and Pharmacodynamics of Intravenous Levofloxacin in Patients with Early-Onset Ventilator-Associated Pneumonia. Clinical Pharmacokinetics, 2003, 42, 589-598.	3.5	53

#	ARTICLE	IF	CITATIONS
199	Disposition of Liposomal Daunorubicin During Cotreatment with Cytarabine in Patients with Leukaemia. <i>Clinical Pharmacokinetics</i> , 2003, 42, 851-862.	3.5	11
200	Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 971-975.	3.0	120
201	Levofloxacin Disposition in Cerebrospinal Fluid in Patients with External Ventriculostomy. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3104-3108.	3.2	51
202	Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 101-106.	3.0	33
203	Preface. <i>Journal of Chemotherapy</i> , 2003, 15, 3-3.	1.5	7
204	Urinary Pharmacokinetics and Theoretical Pharmacodynamics of Intravenous Levofloxacin in Intensive Care Unit Patients Treated with 500 mg b.i.d. for Ventilator-Associated Pneumonia. <i>Journal of Chemotherapy</i> , 2003, 15, 563-567.	1.5	14
205	Quale Ruolo per i Fluorochinoloni in Terapia Intensiva?. <i>Journal of Chemotherapy</i> , 2003, 15, 5-10.	1.5	9
206	What is the Role of Fluoroquinolones in Intensive Care?. <i>Journal of Chemotherapy</i> , 2003, 15, 5-10.	1.5	13
207	TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2002, 20, 326-332.	2.5	52
208	MEGX disposition in critically-ill trauma patients: subsequent assessments during the first week following trauma. <i>Fundamental and Clinical Pharmacology</i> , 2002, 16, 519-525.	1.9	2
209	Pharmacokinetic Aspects of Treating Infections in the Intensive Care Unit. <i>Clinical Pharmacokinetics</i> , 2001, 40, 833-868.	3.5	123
210	Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients. <i>Pharmacological Research</i> , 2001, 43, 547-551.	7.1	6
211	Protocol implementation in hospital infection control practice: an Italian experience of preoperative antibiotic prophylaxis. <i>Journal of Hospital Infection</i> , 2001, 47, 288-293.	2.9	16
212	Cyclosporine dose fractioning might affect renal function in stable heart transplanted patients. <i>Transplantation Proceedings</i> , 2001, 33, 3151-3153.	0.6	2
213	Cerebrospinal Fluid Penetration of Levofloxacin in Patients with Spontaneous Acute Bacterial Meningitis. <i>Clinical Infectious Diseases</i> , 2001, 33, e109-e111.	5.8	38
214	Therapeutic Drug Monitoring—Guided High Teicoplanin Dosage Regimen Required to Treat a Hypoalbuminemic Renal Transplant Patient Undergoing Continuous Venovenous Hemofiltration. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 587-588.	2.0	25
215	Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 279-286.	2.3	26
216	High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 45, 329-335.	3.0	101

#	ARTICLE	IF	CITATIONS
217	Optimisation of Vancomycin Regimen in Neutropenic Haematological Patients with Normal Renal Function. <i>Clinical Drug Investigation</i> , 2000, 19, 213-218.	2.2	10
218	Systemic Vancomycin Overexposure in a Patient With Spinal Cord Injury Who Had Staphylococcal Sepsis and Clostridium difficile Colitis. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 233-234.	2.0	5
219	Ciprofloxacin Disposition in Elderly Patients with LRTI Being Treated with Sequential Therapy (200 mg) Tj ETQq1 1 0.784314 rgBT /Ov the Role of Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 386-391.	2.0	8
220	Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. <i>British Journal of Haematology</i> , 1999, 106, 92-99.	2.5	48
221	Multidrug resistance modulation in vivo: The effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. <i>European Journal of Clinical Pharmacology</i> , 1999, 55, 361-368.	1.9	25
222	CYCLOSPORINE A PHARMACOKINETICS IN RHEUMATOID ARTHRITIS PATIENTS AFTER 6 MONTHS OF METHOTREXATE THERAPY. <i>Pharmacological Research</i> , 1999, 40, 483-486.	7.1	5
223	Isoniazid and its Hydrazine Metabolite in Patients with Tuberculosis. <i>Clinical Drug Investigation</i> , 1999, 17, 145-154.	2.2	12
224	Pharmacokinetic Profile of Two Different Administration Schemes of Teicoplanin. <i>Clinical Drug Investigation</i> , 1999, 18, 47-55.	2.2	9
225	Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. <i>Leukemia</i> , 1998, 12, 1236-1240.	7.2	20
226	LEVODOPA AND 3-O-METHYLDOPA IN CEREBROSPINAL FLUID AFTER LEVODOPA-CARBIDOPA ASSOCIATION. <i>Pharmacological Research</i> , 1997, 35, 313-315.	7.1	28
227	Oral Gabapentin Disposition in Patients with Epilepsy After a High-Protein Meal. <i>Epilepsia</i> , 1997, 38, 1140-1142.	5.1	19
228	CYCLOSPORIN NEPHROTOXICITY IN RELATION TO ITS METABOLISM IN PSORIASIS. <i>Pharmacological Research</i> , 1996, 33, 349-352.	7.1	12
229	Blood Concentrations and Clinical Effect of Cyclosporin in Psoriasis. <i>Therapeutic Drug Monitoring</i> , 1996, 18, 544-548.	2.0	16
230	Effects of different sampling strategies on predictions of blood cyclosporine concentrations in haematological patients with multidrug resistance by bayesian and non-linear least squares methods. <i>Pharmacological Research</i> , 1995, 32, 355-362.	7.1	17
231	Prediction of cyclosporine blood concentrations in hematological patients with multidrug resistance. <i>Pharmacological Research</i> , 1995, 31, 44.	7.1	3
232	Study on the Bactericidal Activity and Synergistic Effect of Neutropenic Rat Serum with Gentamicin. <i>Journal of Chemotherapy</i> , 1994, 6, 117-120.	1.5	0
233	Effect of fluctuations of blood cyclosporine concentrations on renal function. <i>Transplantation Proceedings</i> , 1994, 26, 2574-5.	0.6	4
234	Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats. <i>Biomaterials</i> , 1993, 14, 1154-1160.	11.4	198

#	ARTICLE	IF	CITATIONS
235	Comparison of the Antibacterial Activity and Synergistic Activity Towards Antibiotics of Different Mammalian Sera. <i>Journal of Chemotherapy</i> , 1993, 5, 10-13.	1.5	1
236	A Comparative Analysis of the Urinary Excretion Profiles of Mesna and Argimesna Following Oral Administration to Healthy Volunteers. <i>Drug Investigation</i> , 1992, 4, 391-394.	0.6	0
237	Serum concentrations of sodium 2-mercaptoethanesulfonate (MESNA) and its metabolite, disulfide form (DIMESNA), in volunteers after oral dosing: A comparison between mesna and argimesna.. <i>Pharmacological Research</i> , 1992, 25, 85-86.	7.1	2
238	Enhancement of In-Vitro Activity of Ofloxacin and Gentamicin by Rat Serum. <i>Journal of Chemotherapy</i> , 1990, 2, 368-370.	1.5	4
239	Nosocomial Pneumonia: Strategies for Management: General Pharmacological Considerations and Dose Adjustment in Antibiotic Therapy for HAP. , 0, , 173-189.		0